© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 81305 pertains to the molecular genetic testing of the MYD88 gene, specifically analyzing the p.Leu265Pro (L265P) variant. This gene is crucial for the immune response, as it encodes a protein that acts as an adapter, facilitating communication between external signals and internal cellular responses. The MYD88 gene is located on the short arm of chromosome 3 at position 22.2 (3p22.2). The identification of the L265P variant is particularly significant in the context of Waldenstrom’s macroglobulinemia and lymphoplasmacytic leukemia, both of which are types of cancers that originate from B lymphocytes. The L265P mutation is an acquired single point mutation that results in the substitution of the amino acid leucine with proline at position 265 of the MYD88 protein. This mutation is found exclusively in the abnormal white blood cells associated with these conditions. Waldenstrom’s macroglobulinemia is characterized by a gradual increase in abnormal white blood cells and an overproduction of immunoglobulin M (IgM), leading to various symptoms such as fatigue, unusual bruising or bleeding, and neurological issues. The testing represented by code 81305 is essential for diagnosing and understanding the underlying genetic factors contributing to these hematological malignancies.
© Copyright 2025 Coding Ahead. All rights reserved.
The MYD88 gene analysis using CPT® Code 81305 is indicated for the following conditions:
The procedure for MYD88 gene analysis involves several key steps to ensure accurate identification of the p.Leu265Pro (L265P) variant:
After the MYD88 gene analysis is completed, the healthcare provider will review the results with the patient. If the L265P variant is detected, it may influence treatment options and management strategies for Waldenstrom's macroglobulinemia or lymphoplasmacytic leukemia. Patients may require additional follow-up testing or monitoring based on the findings. It is important for healthcare providers to discuss the implications of the results, including potential treatment pathways and the significance of the genetic mutation in the context of the patient's overall health and disease progression.
| Short Descr | MYD88 GENE P.LEU265PRO VRNT | Medium Descr | MYD88 GENE ANALYSIS P.LEU265 (L265P) VARIANT | Long Descr | MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Service Paid under Fee Schedule or Payment System other than OPPS | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | AQ | Physician providing a service in an unlisted health professional shortage area (hpsa) | 26 | Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number. | 77 | Repeat procedure by another physician or other qualified health care professional: it may be necessary to indicate that a basic procedure or service was repeated by another physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 77 to the repeated procedure or service. note: this modifier should not be appended to an e/m service. | 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. | GA | Waiver of liability statement issued as required by payer policy, individual case | GV | Attending physician not employed or paid under arrangement by the patient's hospice provider | GW | Service not related to the hospice patient's terminal condition | GZ | Item or service expected to be denied as not reasonable and necessary | Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study | XS | Separate structure, a service that is distinct because it was performed on a separate organ/structure |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2019-01-01 | Added | Added |
Get instant expert-level medical coding assistance.